Hangzhou AGS Medtech(688581.SH) granted 391,500 restricted shares at a price of 70 yuan per share.
Hangzhou AGS Medtech(688581.SH) announcement, the restrictive stock grant conditions stipulated in the company's 2023 restricted stock incentive plan have been achieved. The company has determined September 7, 2023 as the initial grant date for the restricted stocks of this equity incentive plan. It will grant 391,500 restricted stocks at a price of 70 yuan per share to 69 eligible incentive recipients.
Related Articles
TRANSTHERA-B (02617): In 2026, the American Society of Clinical Oncology (ASCO) will release key phase II clinical data on the use of Tenofovir alafenamide as monotherapy for advanced bile duct cancer.
Some mines of China Kings Resources Group (603505.SH) temporarily suspended operations for self-inspection.
MINIEYE (02431) joins hands with Zhongtong to embed "True No Map" into the national logistics network, creating a new sample of technology and scene fusion.
TRANSTHERA-B (02617): In 2026, the American Society of Clinical Oncology (ASCO) will release key phase II clinical data on the use of Tenofovir alafenamide as monotherapy for advanced bile duct cancer.
Some mines of China Kings Resources Group (603505.SH) temporarily suspended operations for self-inspection.
MINIEYE (02431) joins hands with Zhongtong to embed "True No Map" into the national logistics network, creating a new sample of technology and scene fusion.
